Multi-center, randomized, double blind, parallel-arm, placebo controlled trial to determine
whether mepolizumab is more effective than placebo for improving symptoms of dysphagia and
decreasing esophageal eosinophil counts in adults and adolescents with active eosinophilic
esophagitis after an initial 3 month treatment course, and will also assess the impact of an
additional 3 months of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
GlaxoSmithKline Minnesota Gastroenterology, P.A. MNGI Digestive Health, P.A. Northwestern University University of Utah